Andre Dandeneau

518 total citations
7 papers, 426 citations indexed

About

Andre Dandeneau is a scholar working on Oncology, Organic Chemistry and Molecular Biology. According to data from OpenAlex, Andre Dandeneau has authored 7 papers receiving a total of 426 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 3 papers in Organic Chemistry and 3 papers in Molecular Biology. Recurrent topics in Andre Dandeneau's work include HER2/EGFR in Cancer Research (3 papers), Pharmacogenetics and Drug Metabolism (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Andre Dandeneau is often cited by papers focused on HER2/EGFR in Cancer Research (3 papers), Pharmacogenetics and Drug Metabolism (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Andre Dandeneau collaborates with scholars based in United States. Andre Dandeneau's co-authors include David M. Stresser, Charles L. Crespi, Andrew P. Blanchard, Stephanie D. Turner, John C. L. Erve, Vaughn P. Miller, Shangara S. Dehal, Raman Sharma, Christopher Patten and Elke S. Perloff and has published in prestigious journals such as Cancer Research, Molecular Cancer Therapeutics and Drug Metabolism and Disposition.

In The Last Decade

Andre Dandeneau

5 papers receiving 408 citations

Peers

Andre Dandeneau

PHARM

ONCOL

MB

CTM

SPECT

Andrew P. Blanchard United States

Konstantine W. Skordos United States

Jason S. Ngui United States

Margit Spatzenegger Austria

K. Grime United Kingdom

Brooke M. VandenBrink United States

J. C. Bloomer United Kingdom

Weiqiao Chen United States

Matthew A. Hummel United States

Y. Naritomi Japan

Andrew P. Blanchard United States

Andre Dandeneau

351 ×1.2

PHARM

144 ×1.0

ONCOL

140 ×1.4

MB

99 ×1.2

CTM

67 ×1.2

SPECT

Citations per year, relative to Andre Dandeneau Andre Dandeneau (= 1×) peers Andrew P. Blanchard

Countries citing papers authored by Andre Dandeneau

Since Specialization

Citations

This map shows the geographic impact of Andre Dandeneau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andre Dandeneau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andre Dandeneau more than expected).

Fields of papers citing papers by Andre Dandeneau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andre Dandeneau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andre Dandeneau. The network helps show where Andre Dandeneau may publish in the future.

Co-authorship network of co-authors of Andre Dandeneau

This figure shows the co-authorship network connecting the top 25 collaborators of Andre Dandeneau. A scholar is included among the top collaborators of Andre Dandeneau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andre Dandeneau. Andre Dandeneau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Whiteman, Kathleen R., Charlene A. Audette, Andre Dandeneau, et al.. (2014). Abstract 2644: Antibody-drug conjugates (ADCs) with a novel DNA-alkylating agent, DGN462, are highly potent in vitro and in vivo against human cancer models. Cancer Research. 74(19_Supplement). 2644–2644. 4 indexed citations

2.

Singh, Rajeeva, Nathan Fishkin, Yelena Kovtun, et al.. (2013). Abstract C164: New tri-glycyl peptide linker offers advantages for maytansinoid antibody-drug conjugates (ADCs).. Molecular Cancer Therapeutics. 12(11_Supplement). C164–C164.

3.

Whiteman, Kathleen R., Holly A. Johnson, Alan Wilhelm, et al.. (2013). Abstract C162: Antibody-Drug Conjugates (ADCs) with novel IGN DNA-alkylating agents display potent antigen-specific activity against hematologic and solid tumor xenograft models.. Molecular Cancer Therapeutics. 12(11_Supplement). C162–C162.

4.

Stresser, David M., et al.. (2009). Differential Time- and NADPH-Dependent Inhibition of CYP2C19 by Enantiomers of Fluoxetine. Drug Metabolism and Disposition. 37(4). 695–698. 16 indexed citations

5.

Perloff, Elke S., et al.. (2009). Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC₅₀shift approach facilitatesk_inactassay design. Xenobiotica. 39(2). 99–112. 71 indexed citations

6.

Stresser, David M., Andrew P. Blanchard, Raman Sharma, et al.. (2004). HIGHLY SELECTIVE INHIBITION OF HUMAN CYP3A IN VITRO BY AZAMULIN AND EVIDENCE THAT INHIBITION IS IRREVERSIBLE. Drug Metabolism and Disposition. 32(1). 105–112. 115 indexed citations

7.

Stresser, David M., Andrew P. Blanchard, Stephanie D. Turner, et al.. (2000). Substrate-Dependent Modulation of CYP3A4 Catalytic Activity: Analysis of 27 Test Compounds with Four Fluorometric Substrates. Drug Metabolism and Disposition. 28(12). 1440–1448. 220 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact